Rocket Pharmaceuticals, Inc.
RCKT
$7.88
$0.192.47%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.00% | 40.71% | 35.06% | 28.54% | 26.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.45% | 3.45% | 4.70% | 8.98% | 16.32% |
| Operating Income | -6.45% | -3.45% | -4.70% | -8.98% | -16.32% |
| Income Before Tax | -5.35% | -2.15% | -1.91% | -5.10% | -10.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.35% | -2.15% | -1.91% | -5.10% | -10.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.35% | -2.15% | -1.91% | -5.10% | -10.70% |
| EBIT | -6.45% | -3.45% | -4.70% | -8.98% | -16.32% |
| EBITDA | -5.72% | -2.75% | -4.22% | -8.78% | -16.41% |
| EPS Basic | 7.00% | 14.34% | 16.29% | 14.46% | 10.53% |
| Normalized Basic EPS | 7.06% | 13.65% | 14.61% | 11.49% | 6.34% |
| EPS Diluted | 7.00% | 14.34% | 16.29% | 14.46% | 10.53% |
| Normalized Diluted EPS | 7.06% | 13.65% | 14.61% | 11.49% | 6.34% |
| Average Basic Shares Outstanding | 12.83% | 18.81% | 21.48% | 23.22% | 24.83% |
| Average Diluted Shares Outstanding | 12.83% | 18.81% | 21.48% | 23.22% | 24.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
